製品名:Pyridine, 6-bromo-2-(difluoromethyl)-3-fluoro-

IUPAC Name:6-bromo-2-(difluoromethyl)-3-fluoropyridine

CAS番号:1806763-56-3
分子式:C6H3BrF3N
純度:95%+
カタログ番号:CM758850
分子量:226

包装単位 有効在庫 価格(USD) 数量

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:1806763-56-3
分子式:C6H3BrF3N
融点:-
SMILESコード:FC(F)C1=NC(Br)=CC=C1F
密度:
カタログ番号:CM758850
分子量:226
沸点:
MDL番号:MFCD25477698
保管方法:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

LX9211
Diabetes Care, a peer-reviewed journal of the American Diabetes Association publishes the data from Lexicon’s RELIEF-DPN 1 phase 2 study of LX9211. Adaptor-Associated Kinase 1 (AAK1) is linked to clathrin-mediated endocytosis, and plays a critical role in neuropathic pain and various neurological disorders.
Lexicon’s LX9211 is a selective small molecule inhibitor of AAK1, that is developed as a novel non-opioid approach to neuropathic pain. LX9211 is designed to become an efficacious treatment for moderate-to-severe pain due to diabetic peripheral neuropathic pain (DPNP), which is difficult to manage with current approved medications.
LX9211 is in late-stage development, and the patient enrollment of Phase 2b study will be completed by 2024. Its top-line data is expected in Q2 2025. Lexicon received Fast Track Designation from the FDA for LX9211 in DPNP in 2020.

Related Products